CVS Plans Historic Split: Pharmacy Chain Separates From Aetna and Caremark

CVS Health is breaking itself in two. The company said Wednesday it will split into two separate public companies by the first half of 2028, as CNBC reported, putting its roughly 9,000 drugstores on one side and its Aetna insurance arm and Caremark pharmacy-benefit business on the other.

It's one of the largest corporate breakups on record, and it unwinds the $78 billion Aetna deal that created the modern CVS in 2018. The Financial Times and the Wall Street Journal had flagged the plan a day earlier, and shares ticked up about 1% in after-hours trading on that news.

The reaction on the actual announcement was a lot less friendly. CVS closed more than 12% lower on Wednesday, even on a day when the Dow jumped more than 1,500 points.

Here's how the pieces fall. The insurance and PBM company keeps the CVS Health name and stays under CEO David Joyner. It will also hold Oak Street Health, Signify Health and the specialty drug business.

The drugstore chain becomes CVS Pharmacy, led by Prem Shah, currently group president of CVS Health. Existing shareholders will own stock in both companies. Boards and additional leadership roles will be named later.

The split didn't arrive alone. CVS also reported third-quarter earnings and revenue that topped Wall Street expectations, with sales climbing to $108.40 billion from $102.87 billion a year ago, and it raised its full-year 2026 guidance.

The timing matters. Joyner has spent the last year running a turnaround that includes about $2 billion in cost cuts, store closures, leadership changes and a push to rein in Medicare Advantage costs. CVS stock is up roughly 70% since he took over in October 2024, and the market value sits near $117 billion.

Joyner told CNBC the move comes "out of a position of strength." He pointed to the recovery in Aetna's Medicare business and solid retail pharmacy results. CVS looked at a breakup in 2024 too, but he said the company lacked the cash and flexibility then.

"This business is a much different business from the one that's been considered three years ago, five years ago, 10 years ago…" — Michael Cherny, Analyst, Leerink Partners, on the CVS pharmacy unit

Cherny's point is that the drugstore side has stabilized. CVS has won share from competitors, and gross margins are steadying thanks to CostVantage, the new pharmacy reimbursement model it introduced last year. That's the case for a standalone CVS Pharmacy: a business that can finally be judged on its own numbers.

The other half has its own logic. Aetna and Caremark sit together as an insurer plus one of the three largest PBMs in the country. Pulling the pharmacies out also takes some political heat off. PBMs face growing bipartisan scrutiny, and Tennessee and Arkansas have passed laws that would bar a company from owning both a PBM and pharmacies. CVS and others are fighting those laws in court.

For investors, the thesis is a classic sum-of-the-parts story. Two cleaner companies could each earn a valuation that fits its business, rather than one blended multiple for a conglomerate. Wednesday's 12% drop suggests plenty of holders aren't convinced yet, which may be where the opportunity sits for anyone willing to wait out a long timeline.

The risk is the thing CVS spent years selling: integration. Investors are asking whether the pharmacy loses its edge by no longer being tied directly to a PBM that negotiates drug prices and manages benefits. Joyner told analysts the synergies "are going to be preserved in commercial agreements between the two organizations," and said "we don't need the integration of an operating structure."

That's a promise, not a contract anyone has seen. And a spin that doesn't close until 2028 leaves a lot of room for execution slips, regulatory changes and a shifting Medicare Advantage picture.

If you already own CVS, nothing changes today. You'll end up holding both companies when the split completes. The things to watch are the leadership and board announcements CVS promised, details on how the two companies will divide debt and cash, and whether the commercial agreements between them look like real, arm's-length deals.

If you're thinking about buying, the market has already handed you a lower entry than Tuesday's. Just know you're buying into a story that plays out over well over a year of paperwork and political noise.

Bottom line: CVS is betting that two focused companies are worth more than one sprawling one, and the stock is asking you to prove it.